Baiyunshan Pharma Gets Nod to Make Amendments to Two Antibiotics

MT Newswires Live

Sep 02

Guangzhou Baiyunshan Pharmaceutical Holdings (SHA:600332, HKG:0874) received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.

The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2564582465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564582465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564582465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564582465","market":"nz","top_or_hot":-1,"title":"Baiyunshan Pharma Gets Nod to Make Amendments to Two Antibiotics","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GZPHF\">Guangzhou Baiyunshan</a> Pharmaceutical Holdings (SHA:600332, HKG:0874) received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.</p><p>The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharma Gets Nod to Make Amendments to Two Antibiotics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharma Gets Nod to Make Amendments to Two Antibiotics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-02 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GZPHF\">Guangzhou Baiyunshan</a> Pharmaceutical Holdings (SHA:600332, HKG:0874) received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.</p><p>The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600332","symbol_name":"白云山","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2564582465","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564582465","pubTimestamp":1756780547,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical Holdings  received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0097":"医药电商","BK0028":"国家队","BK0239":"医药制造","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0188":"融资融券","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK1515":"抗疫概念","BK0070":"员工持股","BK0012":"证金概念","BK1606":"中医药概念","BK0096":"民营医院","BK0196":"行业龙头","BK0175":"白马股","00874":"白云山"},"translate_title":"白云山制药获准对两种抗生素进行修改","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9,"00874":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical Holdings (SHA:600332, HKG:0874) received approval from China's National Medical Products Administration to make changes to two antibiotics after passing the regulator's consistency evaluation, according to a Shanghai bourse filing on Tuesday.The pharmaceutical company will be able to change the drug quality standards and packaging of cefoperazone sodium and sulbactam sodium for injection and clindamycin phosphate injection, as well as the latter's formulation process.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}